Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imricor Medical SystemsASX:IMR -1.79%41 Cash-to-Debt is 1.68 as of Jun. 2026, which is 1% below its 10-year median of 1.70. GuruFocus rates ASX:IMR with a GF Score™ of 41/100 and a GF Value™ of A$0.16 (Significantly Overvalued). The stock has 11 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Imricor Medical Systems ranks better than 50.83% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Imricor Medical Systems's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.68.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Imricor Medical Systemscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Imricor Medical Systems's Cash-to-Debt or its related term are showing as below:
ASX:IMR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 1.7 Max: 32.58
Current: 1.68
During the past 8 years, Imricor Medical Systems's highest Cash to Debt Ratio was 32.58. The lowest was 0.08. And the median was 1.70.
ASX:IMR's Cash-to-Debt is ranked better than 50.83% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.61
vs ASX:IMR: 1.68
Imricor Medical Systems (ASX:IMR) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Imricor Medical Systems Cash-to-Debt Related Terms
Imricor Medical Systems Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Imricor Medical Systems's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imricor Medical Systems Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Imricor Medical Systems's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imricor Medical Systems (ASX:IMR) has a Cash-to-Debt of 1.68 as of Jun. 2026. This is near median its historical median of 1.70. Over the past decade, Imricor Medical Systems' Cash-to-Debt has ranged from 0.08 to 32.58. According to the industry distribution chart, Imricor Medical Systems ranks #414 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 49.2%.
Is Imricor Medical Systems' Cash-to-Debt too high?
Imricor Medical Systems' current Cash-to-Debt of 1.68 is near median its 10-year median of 1.70. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 32.58. The Medical Devices & Instruments industry median Cash-to-Debt is 1.61. Imricor Medical Systems' value of 1.68 is 4.3% above this industry median. Based on the distribution chart, Imricor Medical Systems ranks #414 out of 842 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Imricor Medical Systems has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #414 out of 842 companies for Cash-to-Debt. This puts Imricor Medical Systems in the upper half of its industry. The industry median Cash-to-Debt is 1.61. Imricor Medical Systems' value of 1.68 is 4.3% above this benchmark. Historically, Imricor Medical Systems' own Cash-to-Debt has ranged from 0.08 to 32.58 over the past decade. While the company's 10-year median is 1.70 vs. the industry median of 1.61, Imricor Medical Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.61, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imricor Medical Systems's current Cash-to-Debt of 1.68 is 4.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imricor Medical Systems's current Cash-to-Debt is 1.68, which is near median its own 10-year median of 1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.16, compared to a current price of A$1.93 — trading 1103.1% above its estimated fair value. The current Cash-to-Debt is 1.68, which is near median its 10-year median of 1.70 and 4.3% above the Medical Devices & Instruments industry median of 1.61. Imricor Medical Systems' overall GF Score™ is 41/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current Cash-to-Debt is 1.68 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?
Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued.
The current stock price of A$1.93 is trading 1103.1% above its estimated GF Value™ of A$0.16.
GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.
Key valuation signals for ASX:IMR:
Cash-to-Debt: 1.68 (near median its 10-year median of 1.70)
GF Value™: A$0.16 vs. price of A$1.93 (1103.1% above fair value)
Industry Position: 4.3% above the Medical Devices & Instruments median (#414 of 842)
No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
41GF Score
Get the complete analysis for ASX:IMR
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMR has been successfully added to your 
